Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico

Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico

Myasthenia gravis (MG) is a heterogeneous disease, and there is no unique therapeutic approach for all patients. In 2013 the Myasthenia Gravis American Foundation (MGFA) panel of experts defined refractory MG as the lack of change or deterioration after the use of corticosteroids and two immunosuppr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Suárez H.,Felipe, Urrutia E.,Daniela
Lenguaje:Spanish / Castilian
Publicado: Sociedad Médica de Santiago 2020
Materias:
Biological Therapy
Myasthenia Gravis
Rituximab
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000701031
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872020000701031
record_format dspace
spelling oai:scielo:S0034-988720200007010312020-10-09Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínicoSuárez H.,FelipeUrrutia E.,Daniela Biological Therapy Myasthenia Gravis Rituximab Myasthenia gravis (MG) is a heterogeneous disease, and there is no unique therapeutic approach for all patients. In 2013 the Myasthenia Gravis American Foundation (MGFA) panel of experts defined refractory MG as the lack of change or deterioration after the use of corticosteroids and two immunosuppressive agents, in adequate doses and time. We report a 51-years-old female with MG of bulbar predominance, who presented four myasthenic crises in 17 months despite the use of corticosteroids, azathioprine and mycophenolate. The high costs associated with her hospitalizations, as well as severe caloric - protein malnutrition, the need for tracheostomy and gastrostomy support, led us to use rituximab. The patient evolved with an excellent response, free of crises after 30 months. She gained 12 kg of weight, without tracheostomy and gastrostomy, only using pyridostigmine support 4 times a day.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.7 20202020-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000701031es10.4067/S0034-98872020000701031
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic Biological Therapy
Myasthenia Gravis
Rituximab
spellingShingle Biological Therapy
Myasthenia Gravis
Rituximab
Suárez H.,Felipe
Urrutia E.,Daniela
Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
description Myasthenia gravis (MG) is a heterogeneous disease, and there is no unique therapeutic approach for all patients. In 2013 the Myasthenia Gravis American Foundation (MGFA) panel of experts defined refractory MG as the lack of change or deterioration after the use of corticosteroids and two immunosuppressive agents, in adequate doses and time. We report a 51-years-old female with MG of bulbar predominance, who presented four myasthenic crises in 17 months despite the use of corticosteroids, azathioprine and mycophenolate. The high costs associated with her hospitalizations, as well as severe caloric - protein malnutrition, the need for tracheostomy and gastrostomy support, led us to use rituximab. The patient evolved with an excellent response, free of crises after 30 months. She gained 12 kg of weight, without tracheostomy and gastrostomy, only using pyridostigmine support 4 times a day.
author Suárez H.,Felipe
Urrutia E.,Daniela
author_facet Suárez H.,Felipe
Urrutia E.,Daniela
author_sort Suárez H.,Felipe
title Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
title_short Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
title_full Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
title_fullStr Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
title_full_unstemmed Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
title_sort miastenia gravis refractaria con buena respuesta a rituximab. caso clínico
publisher Sociedad Médica de Santiago
publishDate 2020
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000701031
work_keys_str_mv AT suarezhfelipe miasteniagravisrefractariaconbuenarespuestaarituximabcasoclinico
AT urrutiaedaniela miasteniagravisrefractariaconbuenarespuestaarituximabcasoclinico
_version_ 1718437141714829312

Ejemplares similares